At present, its use is licensed as an add-on treatment for patients aged > 6 years with severe persistent allergic asthma and positive skin test or specific IgE to perennial aeroallergens, FEV1 < 80% predicted, frequent daytime symptoms, or nighttime awakenings, and multiple severe asthma exacerbations despite traditional maintenance therapy (12, 13). This evidence concerns the gene IGHE and asthma.